ClinicalTrials.gg
RecruitingNCT07282743Updated Mar 18, 2026

Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus

A Phase 2 interventional study of GL0034 Dose Level 1 and GL0034 Dose Level 2 in Type II Diabetes Mellitus, sponsored by Sun Pharmaceutical Industries Limited. Recruiting at 21 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-18.

Sponsored by Sun Pharmaceutical Industries Limited · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
285
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 403 studies in Diabetes Mellitus, Type 2 with a site in India — 33 open to participants now, 38 under way, 18 of them phase 3. Diabetes Mellitus, Type 2 · India.

Planned enrollment
233rd of 342
285 · median 463
Started
2026
with 21 others
Phase 2
29 of 403
1 open now
Primary completion
2027-04
later than 16 of 37 live
Registered
374th of 403
by date

Among the 403 studies in Diabetes Mellitus, Type 2 with a site in India, this one is the 233rd largest by planned enrollment of the 342 interventional ones that give a count, is one of 22 that started in 2026, is one of 29 in phase 2, reaches primary completion later than 16 of the 37 other live ones, and was the 374th registered.

Diabetes Mellitus, Type 2

10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

33 of the 403 studies in Diabetes Mellitus, Type 2 with a site in India are open now. Recruiting first, the newest first:

27 more — sign in →

All 33 open studies →

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 403 studies in Diabetes Mellitus, Type 2 with a site in India, or all of them as a file.
02

Study summary

This is a phase II, randomized, double-blind, placebo-controlled study to evaluate the efficacy and tolerability of GL0034 among type II diabetes mellitus subjects who are obese or overweight with weight-related comorbidities. Subjects will be put on either one of the four treatment arms (GL0034, once a week, subcutaneous injection) or placebo arm (once a week, subcutaneous injection) following initial dose-up titration that takes up to approximately 20 weeks. The primary end point is change in HbA1c levels from baseline (Week 0) to Week 36 following treatments in all participants.

03

Conditions studied

  • Type II Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant is willing and able to sign a written ICF or e-ICF.
  2. Men or women ≥18 years of age at the time of signing ICF or e-ICF.
  3. Participant was diagnosed with type II diabetes mellitus at least 180 days prior to the day of screening.
  4. Participant has a level of 7.0 - 10.5%, both inclusive, at the time of screening.
  5. Participant has a stable ≥27 kg/m2 for at least 90 days prior to screening.
  6. Participant is able and willing to undergo fasting blood draw (i.e. at least 8 hours after last eating or drinking) as well as 7-point SMBG check for 3 consecutive days prior to designated scheduled visits by using a home glucometer that is provided by the study site.
  7. Participant on stable daily doses of metformin for at least 90 days prior to screening.
  8. Participant who are on metformin and not the following agents for at least 3 months prior to screening: DPP-4 inhibitors, alpha-glucosidase enzyme inhibitors, sulfonylureas, sodium-glucose transport 2 inhibitors, amylin analogues, thiazolidinediones, any insulin product, herbals, or ayurvedic agents. Participants are encouraged to follow the standard of care in their study regions, including appropriate diet and lifestyle modifications, rather than make abrupt change in the diabetic management prior to screening without consulting their physicians.
  9. If participant is a woman of (WOCP)*, she must agree to use a highly effective method of during the study in conjunction with a barrier method of contraception, and continue the same contraception method at least one months after the last dose of study drug. Highly effective methods of contraception include one of the following: intrauterine device, injectable hormonal contraceptive, contraceptive patch or implant, partner's vasectomy, bilateral tubal occlusion, and sexual abstinence.

    *WOCP includes women who are not surgically sterilized [using hysterectomy/bilateral salpingectomy/bilateral oophorectomy] or [defined as 12 consecutive months of amenorrhea without an alternative medical cause].

  10. Male participants with female partners of child-bearing potential must use a barrier method of contraception (e.g., condom) if not surgically sterile (i.e., vasectomy) during the study. In addition, male participants agree to use the same method of contraception for an additional 30 days after the last IP dose and refrain from donating sperm during this period. In the event that the female partner of the male participant becomes pregnant during the study period + 30 days after the last IP dose, an ICF will be provided to the female partner in order to monitor the female partner, pregnancy, and the newborn.
  11. If participant is a WOCP, she must have a negative serum pregnancy test (SPT) at Screening and a negative urine pregnancy at baseline, with results available before IP administration.
  12. Participant is willing and able to comply with the study protocol, visit schedule, and other study-related instructions and procedures.
  13. Participant is willing and able to independently record the response on various scales and make entries using the e-Patient reported outcomes (ePRO) device.

Exclusion criteria

Exclusion Criteria:

  1. Participants who have a history of type I diabetes mellitus.
  2. A self-reported change in >5% of body weight within 90 days before screening irrespective of medical records.
  3. History of pancreatitis (acute or chronic) or >3 hypoglycemic episodes (blood glucose level \<70 mg/dL or 3.9 mmol/L) within 90 days prior to screening.
  4. Diagnosis of chronic kidney disease with estimated \<60.
  5. Poorly controlled hypertension with systolic blood pressure >160 mmHg and/or diastolic blood pressure >100 mmHg.
  6. Poorly controlled hypothyroidism defined as thyroid-stimulating hormone >6 mIU/L or \<0.4 mIU/L.
  7. Diabetes mellitus and/or obesity that is induced by endocrine disorders (e.g. Cushing Syndrome) or medication use (e.g. ) as judged by the Investigator.
  8. Previous surgical treatment for obesity (liposuction and/or abdominoplasty performed >1 year before screening is allowed). Previous or planned (during the trial period) obesity treatment with surgery or a weight loss device. However, previous interventions that, due to reversal or removal, does not have any influence on the participant's weight, in the opinion of the Investigator, are allowed.
  9. History of major depressive disorder within 2 years before randomization.
  10. History of other severe psychiatric illnesses (i.e. schizophrenia, bipolar disorder).
  11. Any lifetime history of a suicidal attempt.
  12. Participants with any medical condition [i.e. gastroparesis, uncontrolled gastroesophageal reflux disease, or diarrhea with or without a diagnosis of a diagnosis of irritable bowel syndrome] that, in the opinion of the Investigator, can confound study efficacy assessments or safety concerns.
  13. Participant had a myocardial infarction, unstable angina pectoris, or ischemic stroke within the past 6 months prior to IP administration.
  14. Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, sudden cardiac death, unexplained death, long syndrome, or death from a primary dysrhythmia potentially associated with QT prolongation in any family member.
  15. Surgery scheduled for the trial duration period, except for very minor surgical procedures in the opinion of the Investigator.
  16. Participants with active .

    Note: participants with past history of malignancy may be included if:

    • Participant has history of basal cell or in-situ squamous cell carcinoma of skin that has been adequately treated and resolved, per Investigator's judgement.
    • Participant has history of other malignancy that have been adequately treated with no evidence of recurrence/relapse within the last 5 years, per Investigator's judgement.
  17. Presence of diabetic retinopathy [both nonproliferative diabetic retinopathy and proliferative diabetic retinopathy]) or maculopathy in either eye that was verified by a fundoscopic examination within 90 days prior to screening or during the study.
  18. Known moderate to severe coronary, carotid, or peripheral vascular disease that has planned or will likely need revascularization during the study.
  19. Participants with any other condition, which in the opinion of the Investigator, precludes participation in the study (either poses an unacceptable risk to the participant or interferes with assessment/interpretation of study outcomes).
  20. Known to the study IP or its .
  21. History of alcohol or drug abuse in the previous two years (Alcohol abuse in this study is defined as >14 standard drinks per week in men or >7 standard drinks per week in women ± a history of alcohol withdrawal symptoms ± institutionalized/hospitalized due to alcohol use ± binge drinking with >5 standard drinks on a single occasion in men or >4 standard drinks on a single occasion in women).
  22. Participants are taking, or will start, medications with narrow therapeutic index such as digoxin, warfarin, etc, or those that will prolong QTc interval.
  23. Participants received any medications for the treatment of type II diabetes mellitus other than those stated in the inclusion criteria within 90 days before screening. Short-term insulin treatment for a maximum of 7 days prior to screening is allowed. Prior insulin treatment for gestational diabetes is also allowed.
  24. Participants who have used medications in the family of GLP-1 agonists in the past.
  25. Treatment with any herbal diet supplements, over-the-counter diet medications as an attempt to lose weight within 90 days before screening.
  26. Treatment with orlistat, lorcaserin, zonisamide, topiramate, phentermine, buproprion, or naltrexone that could promote weight loss within 90 days before screening.
  27. Participation in any organized or online weight-reduction program (i.e. Weight Watchers) within 90 days before screening.
  28. Screening calcitonin ≥50 ng/L (pg/mL).
  29. Participants having abnormal values on Screening laboratory tests or other evidence of uncontrolled disease involving any system-organ (e.g., cardiovascular, pulmonary, renal, hepatic, neurological, endocrine, gastrointestinal, psychiatric etc.) that, in the opinion of the Investigator, would put the participant at risk by participating in the study.
  30. Participants with positive urine drug screen [amphetamine, barbiturate, benzodiazepine, cocaine, opiates] with substances that are not part of participant's routine medical care. Tetrahydrocannabinols is acceptable for as long as its use is legally allowed by participant 's home state or country.
  31. Participants have clinically significant abnormality , including QTcF >450 msec for males and >470 msec for females, or at high risk for arrhythmia such as judged by the Investigator conditions listed in Criteria #13 above, brady-arrhythmias, tachy-arrhythmias, ventricular arrhythmias, torsade de pointes, high-degree atrioventricular block, or Class III and IV congestive heart failure.
  32. Pregnant or lactating females.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
285 participants (estimated)

Study arms

  • Experimental
    Arm 1

    Dose Up-titration Period: Participants receive GL0034 starting at Dose Level 1 with titration up to Dose Level 2 for approximately 20 weeks Maintenance Treatment Period: Once participants reach their final designated doses, they will continue to receive the final designated doses by weekly subcutaneous administration until the end of Week 48.

    Drug: GL0034 Dose Level 1 · Drug: GL0034 Dose Level 2

  • Experimental
    Arm 2

    Dose Up-titration Period: Participants receive GL0034 starting at Dose Levels 1 to 3 with titration up to Dose Level 2 for approximately 20 weeks Maintenance Treatment Period: Once participants reach their final designated doses, they will continue to receive the final designated doses by weekly subcutaneous administration until the end of Week 48.

    Drug: GL0034 Dose Level 1 · Drug: GL0034 Dose Level 2 · Drug: GL0034 Dose Level 3

  • Experimental
    Arm 3

    Dose Up-titration Period: Participants receive GL0034 starting at Dose Levels 1 to 4 with titration up to Dose Level 2 for approximately 20 weeks Maintenance Treatment Period: Once participants reach their final designated doses, they will continue to receive the final designated doses by weekly subcutaneous administration until the end of Week 48.

    Drug: GL0034 Dose Level 1 · Drug: GL0034 Dose Level 2 · Drug: GL0034 Dose Level 3 · Drug: GL0034 Dose Level 4

  • Experimental
    Arm 4

    Dose Up-titration Period: Participants receive GL0034 starting at Dose Levels 1 to 6 with titration up to Dose Level 2 for approximately 20 weeks Maintenance Treatment Period: Once participants reach their final designated doses, they will continue to receive the final designated doses by weekly subcutaneous administration until the end of Week 48.

    Drug: GL0034 Dose Level 1 · Drug: GL0034 Dose Level 2 · Drug: GL0034 Dose Level 3 · Drug: GL0034 Dose Level 4 · Drug: GL0034 Dose Level 5 · Drug: GL0034 Dose Level 6

  • Placebo comparator
    Placebo

    Dose Up-titration Period: Participants receive sham placebo up titration, once weekly for approximately 20 weeks. Maintenance Treatment Period: Participants will continue to receive placebo once weekly through subcutaneous administration until the end of Week 48.

    Other: Placebo

Interventions

  • DrugGL0034 Dose Level 1

    Dose 1, once a week

  • DrugGL0034 Dose Level 2

    Dose 2, once a week

  • DrugGL0034 Dose Level 3

    Dose 3, once a week

  • DrugGL0034 Dose Level 4

    Dose 4, once a week

  • DrugGL0034 Dose Level 5

    Dose 5, once a week

  • DrugGL0034 Dose Level 6

    Dose 6, once a week

  • OtherPlacebo

    Placebo, once a week

06

What researchers measure

Primary outcomes

  1. Change in HbA1c levels from baseline (Week 0) to Week 36 following treatments in all participants

    Time frame: Week 36

Secondary outcomes

  1. Number of participants with an HbA1c <7.0%, <6.5%, or <5.7%

    Time frame: Week 36 or Week 48

  2. Change in HbA1c levels from baseline (Week 0) to Week 48 following treatments in all participants

    Time frame: Week 48

  3. Change in HbA1c levels over time from baseline (Week 0) to Week 48 following treatments in all participants

    Time frame: Week 48

  4. Percent change (%) in body weight and BMI from baseline (Week 0) to Week 36, Week 48, and over time from baseline to Week 48 following treatments in all participants.

    Time frame: Week 36 and Week 48

  5. Percent of participants who achieved ≥5%, ≥10%, ≥15%, >20%, >25% weight loss from baseline to Week 36 or Week 48 of treatments in all participants.

    Time frame: Week 36 or Week 48

07

Study locations

21 of 21 sites recruiting
  • Lynn Institute of the Ozarks
    Little Rock, Arkansas 72204, United States
    Recruiting
  • Family First Medical Research Center
    Hialeah Gardens, Florida 33175, United States
    Recruiting
  • Alliance for Multispecialty Research (AMR Clinical) - Wichita East
    Lakeland, Florida 33803, United States
    Recruiting
  • CNS Healthcare - Memphis (Clinical Neuroscience Solutions - Memphis)
    Lakeland, Florida 33803, United States
    Recruiting
  • GTL Medical & Research Group
    Miami, Florida 33173, United States
    Recruiting
  • Florida Institute for Clinical Research LLC
    Orlando, Florida 32835, United States
    Recruiting
  • AMR Clinical, El Dorado
    El Dorado, Kansas 67042, United States
    Recruiting
  • AMR Clinical - Newton
    Newton, Kansas 67114, United States
    Recruiting
  • Lynn Health Science Institute - Oklahoma City
    Oklahoma City, Oklahoma 73112, United States
    Recruiting
  • Endolife Specialty Hospitals Pvt. Ltd.
    Guntur, Andhra Pradesh 522001, India
    Recruiting
  • Life Care Hospital and Research Centre
    Bangalore, Karnataka 560092, India
    Recruiting
  • Government Medical College
    Kozhikode, Kerala 673008, India
    Recruiting
  • Jothydevs Diabetes Research Centre
    Trivandrum, Kerala 695032, India
    Recruiting
  • Nirmal Hospital Private Limited
    Kolhāpur, Maharashtra 416008, India
    Recruiting
  • Topiwala National Medical College & BYL Nair Hospital
    Mumbai, Maharashtra 400008, India
    Recruiting
  • Seth G. S. medical college and KEM hospital
    Mumbai, Maharashtra 400012, India
    Recruiting
  • BSES Municipal General Hospital
    Mumbai, Maharashtra 400058, India
    Recruiting
  • LMMF's Deenanath Mangeshkar Hospital and Research Center
    Pune, Maharashtra 411004, India
    Recruiting
  • Lady Hardinge Medical College and S.S.K. Hospital
    New Delhi, National Capital Territory of Delhi 110001, India
    Recruiting
  • All India Institute of Medical Sciences
    New Delhi, National Capital Territory of Delhi 110029, India
    Recruiting
  • Madras Diabetes Research Foundation (MDRF)
    Chennai, Tamil Nadu 600086, India
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Apr 2027, 15 months after the start.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's planned 15 months is above that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2025
First posted
Dec 15, 2025
StartActual
Jan 20, 2026
Primary completionEst.
Apr 2027
CompletionEst.
Aug 2027
Last update
Mar 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07282743
Responsible party
Sponsor
First posted
Dec 15, 2025
Start date
Jan 20, 2026
Primary completion
Apr 2027 (estimated)
Completion
Aug 2027 (estimated)
Last update
Mar 18, 2026

Study contacts

Head, Regulatory Affairs
Contact
Clinical.Trial@sunpharma.com
9122 66455645

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion